(Metyrapone + oxazepam) is under clinical development by Embera NeuroTherapeutics and currently in Phase II for Substance (Drug) Abuse. According to GlobalData, Phase II drugs for Substance (Drug) ...

In their Review about adrenal insufficiency, Irina Bancos and colleagues suggest that after failure of a short (fragment 1–24) adrenocorticotropic hormone stimulation test (sAST), morning ...

Agents that directly lower ACTH secretion by a pituitary adenoma represent an attractive option for the treatment of Cushing's disease, as these drugs directly target the pathogenesis of disease ...

Why Psychology? Well, I suppose its because if you took most of the most interesting parts of Biology, Anthropology, and Neuroscience, mixed it with a bit of Philosophy, Computer Science, and Medicine ...

Expert Rev Endocrinol Metab. 2013;8(2):183-193. Mitotane reduces cortisol synthesis through the inhibition of 11B-hydroxylase, 18-hydroxylase, 3-α hydroxylase, hydroxysteroid dehydrogenase and ...

Fluvastatin is an HMG-CoA reductase inhibitor, also known as a "statin", prescribed for high cholesterol and triglycerides in certain patients, and decreases the blockages in blood vessels.

The team at the OHSU Pituitary Center treats more than 250 patients at a time for Cushing disease/syndrome — a high number for such a rare illness. This condition is also known as hypercortisolism.

The powerful sedative xylazine has been detected in cannabis vapes. Credit: PavelKant/Shutterstock. The UK government has taken a significant step towards banning xylazine, commonly referred to as the ...

Use any of the following treatments for Cushing's syndrome, as specified: 4 weeks prior to first specimen collection and/or during the study period. Adrenostatic medications (metyrapone, ketoconazole, ...